Abstract
The relation between the cell proliferation marker detected by Ki67 monoclonal antibody and tumour size, node involvement, menopausal status, nuclear oestrogen receptors and disease-free survival has been analysed in 236 consecutive breast cancer patients who presented from December 1986 to October 1989. The patients had a median age of 56 years (26-82) and were followed for a median of 34 months (7-51). Ki67 antigen levels were lower in small tumors and when nuclear oestrogen receptors were positive, but did not correlate with nodal involvement. Preliminary data suggest disease-free survival is longer when Ki67 antigen levels are low.
| Original language | English |
|---|---|
| Pages (from-to) | 33-36 |
| Number of pages | 4 |
| Journal | Breast |
| Volume | 2 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1993 |
Fingerprint
ASJC Scopus subject areas
- Obstetrics and Gynaecology
Cite this
Clinical and prognostic usefulness of immunohistochemical determination of Ki67 in breast cancer. / Gottardi, O.; Scanzi, F.; Zurrida, S.; Bono, A.; Majno, M.; Colombo, P.; Ferrari, M.; Gambacocta, M.; Rossi, N.
In: Breast, Vol. 2, No. 1, 1993, p. 33-36.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical and prognostic usefulness of immunohistochemical determination of Ki67 in breast cancer
AU - Gottardi, O.
AU - Scanzi, F.
AU - Zurrida, S.
AU - Bono, A.
AU - Majno, M.
AU - Colombo, P.
AU - Ferrari, M.
AU - Gambacocta, M.
AU - Rossi, N.
PY - 1993
Y1 - 1993
N2 - The relation between the cell proliferation marker detected by Ki67 monoclonal antibody and tumour size, node involvement, menopausal status, nuclear oestrogen receptors and disease-free survival has been analysed in 236 consecutive breast cancer patients who presented from December 1986 to October 1989. The patients had a median age of 56 years (26-82) and were followed for a median of 34 months (7-51). Ki67 antigen levels were lower in small tumors and when nuclear oestrogen receptors were positive, but did not correlate with nodal involvement. Preliminary data suggest disease-free survival is longer when Ki67 antigen levels are low.
AB - The relation between the cell proliferation marker detected by Ki67 monoclonal antibody and tumour size, node involvement, menopausal status, nuclear oestrogen receptors and disease-free survival has been analysed in 236 consecutive breast cancer patients who presented from December 1986 to October 1989. The patients had a median age of 56 years (26-82) and were followed for a median of 34 months (7-51). Ki67 antigen levels were lower in small tumors and when nuclear oestrogen receptors were positive, but did not correlate with nodal involvement. Preliminary data suggest disease-free survival is longer when Ki67 antigen levels are low.
UR - http://www.scopus.com/inward/record.url?scp=0027256591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027256591&partnerID=8YFLogxK
U2 - 10.1016/0960-9776(93)90034-D
DO - 10.1016/0960-9776(93)90034-D
M3 - Article
AN - SCOPUS:0027256591
VL - 2
SP - 33
EP - 36
JO - Breast
JF - Breast
SN - 0960-9776
IS - 1
ER -